Show simple item record

dc.contributor.authorDenninghoff, Valeria
dc.contributor.authorRusso, Alessandro
dc.contributor.authorde Miguel-Pérez, Diego
dc.contributor.authorMalapelle, Umberto
dc.contributor.authorBenyounes, Amin
dc.contributor.authorGittens, Allison
dc.contributor.authorCardona, Andres Felipe
dc.contributor.authorRolfo, Christian
dc.date.accessioned2021-04-12T18:23:21Z
dc.date.available2021-04-12T18:23:21Z
dc.date.issued2021-04-06
dc.identifier.urihttp://hdl.handle.net/10713/15289
dc.description.abstractSmall cell lung cancer (SCLC) is a highly proliferative lung cancer that is not amenable to surgery in most cases due to the high metastatic potential. Precision medicine has not yet improved patients’ survival due to the lack of actionable mutations. Intra-and intertumoral heterogeneity allow the neoplasms to adapt to various microenvironments and treatments. Further studying this heterogeneous cancer might yield the discovery of actionable mutations. First-line SCLC treatment has added immunotherapy to its armamentarium. There has been renewed interest in SCLC, and numerous clinical trials are underway with novel therapeutic approaches. Understanding the molecular and genetic landscape of this heterogeneous and lethal disease will pave the way for novel drug development. © 2021 by the authors.en_US
dc.description.urihttps://doi.org/10.3390/cancers13071723en_US
dc.language.isoen_USen_US
dc.publisherMDPI AGen_US
dc.relation.ispartofCancersen_US
dc.subjectGene pathwayen_US
dc.subjectPathobiologyen_US
dc.subjectsmall cell lung canceren_US
dc.subjectTargeted therapyen_US
dc.titleSmall cell lung cancer: State of the art of the molecular and genetic landscape and novel perspectiveen_US
dc.typeArticleen_US
dc.identifier.doi10.3390/cancers13071723
dc.source.volume13
dc.source.issue7


This item appears in the following Collection(s)

Show simple item record